Please ensure Javascript is enabled for purposes of website accessibility

Why MannKind Corporation Dropped a Day After It Ran Up

By Brian Orelli, PhD - Updated Oct 11, 2017 at 1:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech is raising cash after seeing its shares triple over the last month.

What happened

MannKind (NASDAQ: MNKD) is down 18% at 12:40 p.m. EDT after the company said it raised approximately $57.7 million net of expenses by selling 10,166,600 shares of common stock at $6 per share. The biotech closed yesterday at $6.23 after an analyst upgrade sent shares higher, so a pullback to at least the offer price was to be expected, but shares are currently trading under $6.

So what

Despite the stock reaction, raising capital now is a good move by MannKind's management. Shares had more than tripled over the last month thanks to a label revision for Afrezza, its inhaled insulin product. MannKind thinks the label change, which describes the time-action profile by dosage strength, should help doctors see the benefits of patients inhaling its insulin rather than using injected insulin.

Selling shares when the price is high allows MannKind to raise the same amount of capital with fewer shares needing to be sold, which results in less dilution for current investors. There's an old biotech adage, "Raise when you can, not when you have to." But MannKind both "could" because of the large run-up in stock price and "had to" because it ended the second quarter with $43.4 million in the bank. That's the best of both worlds.

Doctor talking to a patient

Image source: Getty Images.

Now what

Today's influx of cash gives MannKind a longer runway to get Afrezza's sales headed in the right direction. But starting from a base of $1.5 million in the second quarter -- or $2.6 million counting product shipped that hasn't been recognized as revenue yet -- means MannKind has a long road ahead.

To put it in perspective relative to MannKind's valuation, at the second quarter's run rate, the biotech trades at a price-to-sales ratio around 60, even using the more generous $2.6 million number. Exelixis and Seattle Genetics, two biotechs that have drugs with upcoming label changes expected to increase sales, trade at price-to-sales ratios in the 20s. The label change should help MannKind sell more Afrezza, but much of it is already reflected in the stock price.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.